Glenmark Pharmaceuticals Inc. has announced the upcoming launch of Potassium Phosphates Injection USP in the United States in multiple vial strengths.

The product will be available as 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials. The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi.

Glenmark plans to begin distribution in March 2026. According to IQVIA sales data, the market for these formulations recorded annual sales of about $50.7 million for the 12-month period ending January 2026.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, said the injectable launch will help expand the company’s institutional product portfolio while offering quality and affordable alternatives for patients.